- Zeroing in on canine atopic dermatitis
- What makes dogs itch?
- Retrospective evaluation of Apoquel® (oclacitinib) for the treatment of atopic dermatitis. Part 2: monitoring for side effects.
- Apoquel vs. Atopica: a comparison of two medications to control atopic dermatitis in dogs
- Retrospective evaluation of Apoquel® (oclacitinib) for the treatment of 117 dogs with atopic dermatitis. Part 1: control of pruritus (itch).
Learn more about RESPIT
Subscribe to the SkinVet e-Newsletter!
Tag Archives: dog
By Matt Carnett, DVM and Jon Plant, DVM, DACVD There have been a number of advances in canine atopic dermatitis treatment within the past few years, notably the introduction of the janus kinase inhibitor Apoquel (oclacitinib), manufactured by Zoetis. While … Continue reading
By Jon Plant, DVM, DACVD Atopica® (cyclosporine) and Apoquel® (oclacitinib) are separate and distinct medications. Both are used for controlling the signs and symptoms of atopic dermatitis (“allergies”) in dogs. They are two of the most effective allergy treatments for … Continue reading
Retrospective evaluation of Apoquel® (oclacitinib) for the treatment of 117 dogs with atopic dermatitis. Part 1: control of pruritus (itch).
We started hearing about a new drug to control the itch of allergic dermatitis and canine atopic dermatitis in dogs over 1 year of age at the Vancouver World Congress of Veterinary Dermatology. Like most veterinary dermatologists, I was eager … Continue reading
You will soon have a new tool for the management of itchy dogs. This is going to be a must-have app for veterinarians who treat allergic dermatitis. Among the features of this iOS app are: Pet parent grading and recording … Continue reading
By Jon Plant, DVM, DACVD Scratching, biting, chewing, rubbing, and excessive licking can all be signs of itch (pruritus) in dogs. A number of methods have been developed to try to quantify itching, but these are most useful in research … Continue reading
By Jon Plant, DVM, DACVD How much do we know about Apoquel’s safety? Quite a lot, I would argue. The short-term safety profile, based on the data collected during multiple randomized-controlled trials at recommended doses looks good. In a 28-day … Continue reading